Stocky turns companies like DFTX into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. MNMD's 24/100 Value Compounder Score reflects weak fundamentals with limited profitability or cash generation, while a 100/100 Vulnerability Index signals structural headwinds in psychedelic medicine R&D—regulatory uncertainty, clinical trial risk, and commercialization barriers remain unresolved. Leadership Alignment (51/100) offers modest confidence but insufficient to offset execution and market-adoption risks.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for DFTX:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 42/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates DFTX (MNMD) at 42/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. MNMD's 24/100 Value Compounder Score reflects weak fundamentals with limited profitability or cash generation, while a 100/100 Vulnerability Index signals structural headwinds in psychedelic medicine R&D—regulatory uncerta
MNMD's current Stocky Verdict is 42/100, placing it in the "Cautious" band. This composite combines a 24/100 Compounder score, 51/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for DFTX yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
DFTX scores 51/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
DFTX's Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to DFTX.
Sign up free and unlock the full analysis on MNMD — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for MNMD in the app.
